UY23935A1 - Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida - Google Patents

Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida

Info

Publication number
UY23935A1
UY23935A1 UY23935A UY23935A UY23935A1 UY 23935 A1 UY23935 A1 UY 23935A1 UY 23935 A UY23935 A UY 23935A UY 23935 A UY23935 A UY 23935A UY 23935 A1 UY23935 A1 UY 23935A1
Authority
UY
Uruguay
Prior art keywords
azithromycin
tablet
food
dosage form
dosage forms
Prior art date
Application number
UY23935A
Other languages
English (en)
Inventor
J Curatolo William
H Foulds George
L Friedman Hylar
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY23935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of UY23935A1 publication Critical patent/UY23935A1/es
Priority to UY24614A priority Critical patent/UY24614A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se describe una forma de dosificación en la forma de una tableta que comprende azitromicina, en donde dicha tableta es administrable a un mamífero que ha comido y la cual no exhibe efectos adversos a la comida, que incluye: azitromicina, un desintegrante y opcionalmente otros ingredientes, mezclados y granulado en húmedo, previo a la formación de la mencionada tableta, donde dicha tableta lleva adelante la disolución de por lo menos un 90% de la azitromicina en aproximadamente 30 minutos cuando una cantidad de tal forma de dosificación equivalente a 200 mg de azitromicina se ensaya conforme al Ensayo USO < 711 > en un aparato de disolución USP-2 bajo condiciones tan severas como las siguientes: - 900 ml de buffer de fosfato de sodio, - pH 6, - 37º C, - con paletas que giran a 100 rpm, considerando que dicha forma de dosificación contiene una cantidad de un óxido o hidróxido de metal alcalino-terreo menor que la suficienta para quedar enmascarada a gusto. La azitromicina es de utilidad para el tratamiento de infecciones microbianas.
UY23935A 1994-04-29 1995-03-15 Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida UY23935A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY24614A UY24614A1 (es) 1994-04-29 1997-07-10 Procedimiento para preparar formas de dosificacion de azitromicina

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (1)

Publication Number Publication Date
UY23935A1 true UY23935A1 (es) 1995-09-12

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
UY23935A UY23935A1 (es) 1994-04-29 1995-03-15 Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida

Country Status (31)

Country Link
US (2) US5605889A (es)
EP (1) EP0679400B1 (es)
JP (3) JPH07300420A (es)
KR (1) KR100354310B1 (es)
CN (1) CN1088362C (es)
AP (1) AP566A (es)
AT (1) ATE183395T1 (es)
AU (1) AU709328B2 (es)
CA (1) CA2148071C (es)
CO (1) CO4560547A1 (es)
DE (1) DE69511451T2 (es)
DK (1) DK0679400T3 (es)
DZ (1) DZ1877A1 (es)
ES (1) ES2136247T3 (es)
FI (1) FI952060A (es)
GR (1) GR3031290T3 (es)
HU (1) HUT75244A (es)
IL (1) IL113437A (es)
LV (1) LV10918B (es)
MA (1) MA23533A1 (es)
NO (1) NO314386B1 (es)
NZ (1) NZ548384A (es)
OA (1) OA10151A (es)
RU (1) RU2128998C1 (es)
SI (1) SI0679400T1 (es)
TN (1) TNSN95046A1 (es)
TW (1) TW499311B (es)
UA (1) UA34464C2 (es)
UY (1) UY23935A1 (es)
YU (1) YU49483B (es)
ZA (1) ZA953439B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130311C1 (ru) * 1994-05-06 1999-05-20 Пфайзер Инк. Лекарственные формы азитромицина с контролируемым высвобождением
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
EA000361B1 (ru) * 1995-02-08 1999-06-24 Яманучи Юроп Б.В. Способ приготовления гранулята, содержащего активный при пероральном введении бета-лактамный антибиотик
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
ES2191987T3 (es) * 1997-12-22 2003-09-16 Schering Corp Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion.
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
BR0009437A (pt) * 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
ATE320441T1 (de) * 2000-07-25 2006-04-15 Silanes Sa De Cv Lab Einstufiges verfahren zur herstellung von 7,16-
DE60114028T2 (de) * 2000-08-23 2006-07-13 Wockhardt Ltd. Verfahren zur herstellung von wasserfreiem azithromycin
AU2002232406C1 (en) * 2000-11-06 2009-03-05 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
AU2002214290A1 (en) * 2000-11-15 2002-05-27 Masao Sugamata Preventives or remedies for endometriosis or uterine myoma
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1671979B1 (en) 2001-05-22 2008-08-13 Pfizer Products Inc. New Cristal Form of Azithromycin
EE200300575A (et) * 2001-05-22 2004-04-15 Pfizer Products Inc. Asitromütsiini kristalsed vormid
CZ2004232A3 (cs) * 2001-08-21 2005-10-12 Pfizer Products Inc. Jednorázová dávka azithromycinu
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
HUP0402291A2 (hu) * 2001-10-18 2005-03-29 Teva Pharmaceutical Industries Ltd. Stabilizált azithromycin összetételek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1455757A2 (en) * 2001-12-21 2004-09-15 Pfizer Products Inc. Methods for wet granulating azithromycin
EP1455758A1 (en) * 2001-12-21 2004-09-15 Pfizer Products Inc. Directly compressible formulations of azithromycin
EP1476191A2 (en) * 2002-01-16 2004-11-17 Pepgen Corporation Oral administration of interferon-tau
RU2283092C2 (ru) * 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
AU2003209475A1 (en) * 2002-03-07 2003-09-16 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
CA2517004A1 (en) * 2003-02-19 2004-09-02 Teva Pharmaceutical Industries Ltd. Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
AU2004238253B2 (en) * 2003-05-06 2011-01-27 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
PL1648473T3 (pl) * 2003-07-24 2009-07-31 Pliva Hrvatska D O O Pojedyncza dawka szybko rozpuszczającej się azytromycyny
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
BRPI0417360A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc método para a preparação de multiparticulados farmacêuticos
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
UA78793C2 (en) * 2003-12-04 2007-04-25 Pfizer Prod Inc Oral dosage form of azitromycin with decreased side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
JP2007517055A (ja) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答の増強
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
MX2007009088A (es) * 2005-01-27 2007-09-13 Alembic Ltd Formulacion de liberacion extendida de levetiracetam.
DE602005015765D1 (de) * 2005-03-07 2009-09-10 Teva Pharma Azithromycin-puolver für orale suspensionszusammensetzungen
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
RU2398586C3 (ru) 2005-05-26 2017-10-04 Сумитомо Дайниппон Фарма Ко., Лтд. Фармацевтическая композиция
US20080274178A1 (en) * 2005-08-10 2008-11-06 Shionogi & Co., Ltd. Orally Disintegrating Tablet
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
PL2554168T3 (pl) 2010-03-29 2018-05-30 Astellas Pharma Inc. Kompozycja farmaceutyczna do kontrolowanego uwalniania
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
RS61949B1 (sr) 2012-02-06 2021-07-30 Boehringer Ingelheim Animal Health Usa Inc Paraziticidne oralne veterinarske kompozicije koje sadrže sistemski delujuća aktivna sredstva, metodi i primene istih
IN2014MN01706A (es) 2012-02-28 2015-05-29 Seoul Pharma Co Ltd
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
US20150132382A1 (en) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Ltd. Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
UA27040C2 (uk) 1987-07-09 2000-02-28 Пфайзер Інк. Кристалічhий дигідрат азитроміциhу та спосіб одержаhhя кристалічhого дигідрату азитроміциhу
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0553353A1 (en) * 1990-10-15 1993-08-04 Taisho Pharmaceutical Co. Ltd 2'-modified erythromycin or derivative thereof
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
JPH09503504A (ja) 1993-10-01 1997-04-08 ザ、プロクター、エンド、ギャンブル、カンパニー 成人歯周炎の治療のためのアジトロマイシンの用途とこの用途のための局所組成物
RU2130311C1 (ru) 1994-05-06 1999-05-20 Пфайзер Инк. Лекарственные формы азитромицина с контролируемым высвобождением

Also Published As

Publication number Publication date
DE69511451T2 (de) 1999-12-09
JP2005015466A (ja) 2005-01-20
DE69511451D1 (de) 1999-09-23
CN1088362C (zh) 2002-07-31
FI952060A0 (fi) 1995-04-28
AP566A (en) 1996-11-22
FI952060A (fi) 1995-10-30
KR100354310B1 (ko) 2002-12-26
JPH07300420A (ja) 1995-11-14
TW499311B (en) 2002-08-21
AU1771195A (en) 1995-11-09
JP2008231120A (ja) 2008-10-02
US5605889A (en) 1997-02-25
DZ1877A1 (fr) 2002-02-17
NZ548384A (en) 2008-04-30
AU709328B2 (en) 1999-08-26
IL113437A0 (en) 1995-07-31
HU9501206D0 (en) 1995-06-28
MA23533A1 (fr) 1995-12-31
RU2128998C1 (ru) 1999-04-20
ES2136247T3 (es) 1999-11-16
HUT75244A (en) 1997-05-28
OA10151A (en) 1996-12-18
SI0679400T1 (en) 1999-10-31
CO4560547A1 (es) 1998-02-10
TNSN95046A1 (fr) 1996-02-06
USRE39149E1 (en) 2006-06-27
DK0679400T3 (da) 1999-12-06
YU27195A (sh) 1999-03-04
CA2148071A1 (en) 1995-10-30
EP0679400B1 (en) 1999-08-18
RU95106639A (ru) 1997-01-20
NO314386B1 (no) 2003-03-17
GR3031290T3 (en) 1999-12-31
NO951630L (no) 1995-10-30
EP0679400A1 (en) 1995-11-02
CN1114879A (zh) 1996-01-17
ATE183395T1 (de) 1999-09-15
NO951630D0 (no) 1995-04-28
KR950028764A (ko) 1995-11-22
CA2148071C (en) 2000-10-17
IL113437A (en) 2001-04-30
YU49483B (sh) 2006-08-17
AP9500728A0 (en) 1995-04-30
ZA953439B (en) 1996-10-28
UA34464C2 (uk) 2001-03-15
LV10918A (lv) 1995-12-20
LV10918B (en) 1996-06-20

Similar Documents

Publication Publication Date Title
UY23935A1 (es) Formas de dosificación de azitromicina que no presentan efecto alimento adverso con la comida
PT1246920E (pt) Prevenção de afecções associadas ao circovírus porcino 2
BG104644A (en) Novel macrolides
CA2498143A1 (en) Antimicrobial composition and method for use
PE20010977A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
ATE333885T1 (de) Verwendung von sulodexid zur behandlung von reizdarm
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
BR9913738A (pt) Composições e métodos de sanitização
US2649398A (en) Douche composition
SE9802818L (sv) Surdegsprodukt
WO2018083212A1 (en) Microbiome-safe cosmetic cleaning compositions
Ray et al. Effect of thyroid hormones and analogues on ammonia and urea excretion in Lata fish (Ophicephalus punctatus)
JPS5756420A (en) Bath agent
Hellbaum et al. Action of estrogen on release of hypophyseal luteinizing hormone
KR101852574B1 (ko) 패각소성칼슘을 포함하는 주방용 세제 조성물 및 이의 제조방법
Russo et al. The enigma of testicular leukemia: a critical review
Olaniyi et al. a‑tocopherol attenuates acetaminophen‑induced testicular dysfunction in adult male rats
Luoma The effects of propanol, butanol, chlorhexidine, fluoride and combinations on the potassium and phosphate translocation and acid production by Streptococcus mutans
KR970020112A (ko) 결명자 추출물의 제조방법과 이들로된 항산화, 프리라디칼소거, 항돌연변이제 및 안(眼) 노화 방지 안질환예방제
JP7073436B2 (ja) 洗浄用組成物
AR044697A1 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
WO2000025763A3 (de) Phenolderivaten enthaltendes mittel mit proliferationshemmender wirkung auf tumorzellen
AU2019100770A4 (en) IBS Prevention and Treatment (Internal and on bowel exterior)
KR101889958B1 (ko) 물비누를 이용한 친환경 소화약제와 이의 제조방법
US3399264A (en) Antiseptic composition of 9-aminoacridine hydrochloride and benzalkonium hydrochloride

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20150315